Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) have received a consensus recommendation of “Moderate Buy” from the five ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $10.00.

Several research firms have weighed in on AMRX. StockNews.com downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, December 19th. Piper Sandler lifted their price objective on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. Finally, Truist Financial upped their target price on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, October 2nd.

Insider Activity at Amneal Pharmaceuticals

In related news, Director Gautam Patel sold 17,410 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $8.01, for a total transaction of $139,454.10. Following the completion of the transaction, the director now owns 2,031,476 shares of the company’s stock, valued at approximately $16,272,122.76. This represents a 0.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Jason B. Daly sold 43,657 shares of the stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $8.61, for a total transaction of $375,886.77. Following the transaction, the senior vice president now directly owns 13,665 shares in the company, valued at approximately $117,655.65. This represents a 76.16 % decrease in their position. The disclosure for this sale can be found here. Insiders own 17.46% of the company’s stock.

Institutional Trading of Amneal Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Gladius Capital Management LP purchased a new stake in Amneal Pharmaceuticals during the third quarter valued at about $37,000. DekaBank Deutsche Girozentrale acquired a new position in shares of Amneal Pharmaceuticals in the 2nd quarter valued at about $42,000. Xponance Inc. purchased a new stake in shares of Amneal Pharmaceuticals during the 2nd quarter worth about $65,000. Quest Partners LLC acquired a new stake in Amneal Pharmaceuticals during the 3rd quarter worth approximately $84,000. Finally, Profund Advisors LLC increased its position in Amneal Pharmaceuticals by 8.1% during the 2nd quarter. Profund Advisors LLC now owns 22,522 shares of the company’s stock worth $143,000 after purchasing an additional 1,680 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Price Performance

Shares of AMRX opened at $8.06 on Thursday. Amneal Pharmaceuticals has a 1-year low of $5.01 and a 1-year high of $9.48. The stock has a market cap of $2.50 billion, a price-to-earnings ratio of -11.85 and a beta of 1.10. The firm has a 50 day simple moving average of $8.24 and a 200-day simple moving average of $8.03.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.